Advertisement


Andreas Burchert, MD, on AML: Results From the Sormain Trial

2018 ASH Annual Meeting & Exposition

Advertisement

Andreas Burchert, MD, of the Philipps University of Marburg, discusses study findings on sorafenib as maintenance therapy after allogeneic stem cell transplantation for FLT3-ITD–positive acute myeloid leukemia.



Related Videos

Lymphoma

Anas Younes, MD, on DLBCL: Phase III Trial Results

Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, discusses trial findings on ibrutinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in peop...

Leukemia
Lymphoma
Immunotherapy

Julie Vose, MD, MBA, and Merav Bar, MD, on CAR T-Cell Therapy: Late Effects of CD19-Targeted Treatment

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Merav Bar, MD, of the Fred Hutchinson Cancer Research Center, discuss study findings on the ...

Leukemia

Tait D. Shanafelt, MD, on CLL: Results From a Trial of the ECOG-ACRIN Cancer Research Group

Tait D. Shanafelt, MD, of Stanford University, discusses phase III study findings on ibrutinib-based therapy vs standard fludarabine, cyclophosphamide, and rituximab chemoimmunothe...

Lymphoma

Gilles A. Salles, MD, PhD, on DLBCL: Results From the L-Mind Treatment Trial

Gilles A. Salles, MD, PhD, of Centre Hospitalier Lyon Sud, discusses trial findings on the monoclonal antibody MOR208 combined with lenalidomide in people with relapsed or refracto...

Lymphoma

John P. Leonard, MD, on NHL: Results From the AUGMENT Trial

John P. Leonard, MD, of Weill Cornell Medicine/Cornell University, discusses phase III findings on lenalidomide plus rituximab vs rituximab plus placebo for people with relapsed or...

Advertisement

Advertisement



;
Advertisement